ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 907,31
0,99%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Avalo Therapeutics Inc (AVTX)

  7. Avalo Therapeutics Inc (AVTX) Actualités

AVTX

Avalo Therapeutics (AVTX)

Avalo Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AVTX
DateHeureSourceTitreSymboleSociété
24/06/202422h01GlobeNewswire Inc.Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal OfficerNASDAQ:AVTXAvalo Therapeutics Inc
17/06/202413h30GlobeNewswire Inc.Avalo to Present at the Oppenheimer Novel Targets in Immunology SummitNASDAQ:AVTXAvalo Therapeutics Inc
07/06/202413h01Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AVTXAvalo Therapeutics Inc
06/06/202422h03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AVTXAvalo Therapeutics Inc
03/06/202413h20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
23/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
13/05/202418h38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AVTXAvalo Therapeutics Inc
13/05/202413h33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVTXAvalo Therapeutics Inc
13/05/202413h30GlobeNewswire Inc.Avalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
02/04/202413h00GlobeNewswire Inc.Avalo Therapeutics Appoints Biotech Leaders to Board of DirectorsNASDAQ:AVTXAvalo Therapeutics Inc
29/03/202421h01GlobeNewswire Inc.Avalo Reports 2023 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
27/03/202421h01GlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:AVTXAvalo Therapeutics Inc
15/02/202403h13Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
27/12/202313h00GlobeNewswire Inc.Avalo Therapeutics Announces 1-for-240 Reverse Stock SplitNASDAQ:AVTXAvalo Therapeutics Inc
21/12/202322h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
07/12/202313h02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AVTXAvalo Therapeutics Inc
07/12/202313h00GlobeNewswire Inc.Avalo Encourages Stockholders to Vote FOR the Reverse Stock SplitNASDAQ:AVTXAvalo Therapeutics Inc
09/11/202313h00GlobeNewswire Inc.Avalo Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
31/10/202312h00GlobeNewswire Inc.Avalo Completes Divestiture of AVTX-800 SeriesNASDAQ:AVTXAvalo Therapeutics Inc
19/10/202322h15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AVTXAvalo Therapeutics Inc
19/10/202322h01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AVTXAvalo Therapeutics Inc
26/09/202313h00GlobeNewswire Inc.Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and InnovationNASDAQ:AVTXAvalo Therapeutics Inc
12/09/202313h00GlobeNewswire Inc.Avalo Enters into Agreement to Divest AVTX-800 SeriesNASDAQ:AVTXAvalo Therapeutics Inc
06/09/202313h00GlobeNewswire Inc.Avalo to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:AVTXAvalo Therapeutics Inc
07/08/202323h26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AVTXAvalo Therapeutics Inc
03/08/202313h00GlobeNewswire Inc.Avalo Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
06/07/202322h01GlobeNewswire Inc.Avalo to Participate in SVB Securities Therapeutics ForumNASDAQ:AVTXAvalo Therapeutics Inc
29/06/202314h23Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AVTXAvalo Therapeutics Inc
29/06/202300h13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVTXAvalo Therapeutics Inc
28/06/202312h01Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:AVTXAvalo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AVTX

Dernières Valeurs Consultées

NASDAQ
UBSI
United Bankshares
LSE
80DF
Hsbc Bk. 23
LSE
16OZ
Westpac 38
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés